The Toll family of receptors
Toll Like Receptors or TLRs are type I transmembrane proteins of the Interleukin-1 receptor (IL-1R) family that possess an N-terminal leucine-rich repeat (LRR) domain for ligand binding, a single transmembrane domain, and a C-terminal intracellular signaling domain. The TLR C terminus is homologous to the intracellular domain of the IL-1R and is thus referred to as the Toll/IL-1 receptor (TIR) domain. TLRs are expressed at the cell membrane and in sub cellular compartments such as the endosomes and are widely expressed in many cell types, including non hematopoietic epithelial, endothelial cells. Although most cell types express only a select subset of these receptors. However hematopoietically derived sentinel cells, such as macrophages, neutrophils, and dendritic cells (DCs), express most of the TLRs, with some variation in different subsets, e.g., between conventional DCs and plasmacytoid DCs. Thus far, 13 mammalian TLRs, 10 in humans and 13 in mice, have been identified (Beutler 2004). TLRs 1– 9 are conserved among humans and mice, yet TLR10 is present only in humans and TLR11 is functional only in mice. Although much is known about the ligands and signaling pathways of TLRs 1–9 and 11, the biological roles of TLRs 10, 12, and 13 remain unclear, as their expression patterns, ligands, and modes of signaling have yet to be defined.
TLRs mediate initial responses in innate immunity and are required for the development of the adaptive immune response. Toll-like receptors (TLRs) enable innate immune recognition of endogenous and exogenous prototypic ligands. They also orchestrate innate and adaptive immune response to infection, inflammation, and tissue injury. Given their significance in the immune response, it is not surprising that genetic variations of TLRs can affect their function and by extension affect the response of the organism to environmental stimuli. The genetics of TLRs provides important insights in gene-environment interactions in health and disease, and it may enable scientists to assess patients’ susceptibility to diseases or predict their response to treatments.
Evolutionary genetics of TLRs
In the domain of the evolutionary genetics of infectious diseases, the aim is to identify the evolutionary footprints of natural selection exerted by past infections in the genome of present day healthy human populations. Given the tremendous selective pressure that pathogens have exerted in the past, and continue to exert, it is hardly surprising that some of the strongest evidence for selection, of various types and intensities, in the human genome has actually been obtained for genes involved in immunity or host defense as immunity related functions seem to be a privileged target of natural selection in the human species as a whole (with respect to other primates) and in different human populations from diverse geographic regions.
Phylogenetic studies have indicated an ancient origin for TLR genes, some 700 million years ago, suggesting that TLR-mediated immune responses originated in the common ancestor of bilaterian animals. However, several recent, independent lines of evidence genomic, phylogenetic, and functional data have suggested that the similarities and differences between TLR-mediated innate immunity functions in insects and vertebrates may instead have resulted from convergent evolution. Convergent evolution refers the phenomenon where organisms that are not closely related independently evolve similar traits as a result of having to adapt to similar environments or ecological niches. Another study showed that vertebrate TLRs can be divided into six major families, with all the TLRs within a given family recognizing the same general or speciﬁc class of microbial compound. The patterns of interspecies divergence and levels of polymorphism in various primates, including humans, have recently been investigated. Signatures of accelerated evolution (species-wide positive selection) was found across primate species for most TLRs, with the strongest evidence of this obtained for TLR1 and TLR4, which have been independently targeted by positive selection. However, within each primate species, the patterns of nucleotide variation were generally constrained.
TLRs and Diseases
TLRs In Pulmonary Diseases
Current data suggest that TLR signaling can modify both allergic asthma and chronic obstructive pulmonary disease (COPD). Activation of TLRs can be either beneﬁcial or detrimental depending on many host factors, as well as dose, duration, and intensity of expo-sure to TLR ligands. Multiple epidemiologic studies have associated childhood exposure to TLR ligands with protection against develop-ing allergic asthma later in life (the “hygiene hypothesis”); for example, individuals living on farms have a reduced risk of developing hay fever or asthma. The most extensively studied TLR is TLR4. A study of asthma speciﬁcally associated with LPS in house dust showed that people with the TLR4 polymorphism Asp299Gly had a de-creased risk of bronchoreactivity. These observations are consistent with the hypothesis that LPS can exacerbate existing airway inﬂammation and that individuals with the Asp299Gly polymorphism have diminished pulmonary responses to LPS.
TLRs In CardioVascular Disease
Atherosclerosis is an inﬂammatory process, and innate immunity has been shown to par-ticipate in the development and rupture of atherosclerotic plaques. TLR4 polymorphisms that render the receptor less responsive to its ligands would therefore be expected to hinder the development and progression of atherosclerosis. Indeed, the Asp299Gly poly-morphism has been associated with decreased atherosclerosis, decreased risk for acute coronary events , and an improved re-sponse to statin treatment. The exact mechanism of this beneﬁcial effect is un-known; however, TLRs are expressed on several cells that participate in the atherosclerotic plaque, such as macrophages, dendritic cells, endothelia, smooth muscle cells, and lymphocytes. As the involvement of innate immunity in atherosclerosis is better understood, more genetic factors are likely to be discovered to inﬂuence both the suscep-tibility to cardiovascular disease and the response to treatment.
TLRs In Cancer
In Cancer inﬂammation acts as a double-edged sword. On one hand, chronic inﬂammation is associated with carcinogenesis, and cancer is a complication of chronic inﬂammatory conditions such as Crohn’s disease, chronic cystitis, and hepatitis. TLR activation leads to production of NF-κ B, which is associated with carcinogenesis and chemoresistance On the other hand, the immune system is necessary for the elimination of malignant cells, and immunosuppressed patients are a risk for the development of cancer. Immunotherapy (i.e., use of the patient’s own immune system to combat cancer, with the aid of vaccination or adjuvants) has been gaining attention as a potential treatment option in cancer. Indeed, we are only now beginning to understand how cancer cells evade elimination by modifying the innate and adaptive immune responses of the host. Activation of the immune system may therefore be a viable approach to cancer therapy.
1 . Casanova, Jean-Laurent, Laurent Abel, and Lluis Quintana-Murci. "Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics." Annual review of immunology 29 (2011): 447-491.
2. Pancer, Zeev, and Max D. Cooper. "The evolution of adaptive immunity." Annu. Rev. Immunol. 24 (2006): 497-518.
3. Garantziotis, Stavros, et al. "The Effect of Toll-Like Receptors and Toll-Like Receptor
4. Roach, Jared C., et al. "The evolution of vertebrate Toll-like receptors." Proceedings of the National Academy of Sciences of the United States of America 102.27 (2005): 9577-9582.
5. CE Sawian, SD Lourembam, A Banerjee, S Baruah “ Polymorphisms and expression of TLR4 and 9 in malaria in two ethnic groups of Assam, northeast India” Innate immunity 19 (2), 174-183
Hello! My name is Arunabha Banerjee, and I am the mind behind Biologiks. Leaning new things and teaching biology are my hobbies and passion, it is a continuous journey, and I welcome you all to join with me